During the past decade, Institute of Rheumatology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 6 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Rheumatology" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "4SC AG" with 1 trials sponsored, "Anika Therapeutics, Inc." with 1 trials sponsored, "Can-Fite BioPharma" with 1 trials sponsored and "Fidia Farmaceutici s.p.a." with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Rheumatology" #1 collaborator was "Biogen" with 1 trials as a collaborator, "Charles University, Czech Republic" with 1 trials as a collaborator, "Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic" with 1 trials as a collaborator, "European Commission" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Rheumatology" are "Lupus Nephritis" (3 trials), "Dermatomyositis" (2 trials), "Polymyositis" (2 trials), "Rheumatoid Arthritis" (2 trials) and "Systemic Lupus Erythematosus" (2 trials). Many other conditions were trialed in "Institute of Rheumatology" in a lesser frequency.

Most popular intervention types in "Institute of Rheumatology" are "Drug" (11 trials), "Device" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Methotrexate" (2 trials), "Nintedanib" (2 trials), "Abatacept Active Treatment" (1 trials) and "Abatacept Delayed-Onset Treatment" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Rheumatology" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Institute of Rheumatology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Institute of Rheumatology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Rheumatology, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".